Brief: Pure Biologics Signs Deal With US-Based Presage Biosciences

Multiqure SA

27/12/2022 14:38

Dec 27 (Reuters) - Pure Biologics SA  PUR1.WA :
    * SIGNS DEAL WITH US-BASED PRESAGE BIOSCIENCES
    * DEAL REGARDS FIRST ADMINISTRATION OF PB003 AND PB004
MOLECULES
IN HUMANS, SO-CALLED PHASE 0 CLINICAL TRIAL
    * DEAL IS FOR 2 YEARS
    * DEAL IS LARGELY REFINANCED FROM GRANTS FROM POLAND'S
NATIONAL
CENTER FOR RESEARCH AND DEVELOPMENT
    * ESTIMATED CO'S OWN CONTRIBUTION AT 5 MILLION ZLOTYS
    * UNDER DEAL PRESAGE BIOSCIENCES TO CONDUCT PHASE 0 CLINICAL
TRIAL

Source text for Eikon:  ID:nEM3ZDbpka 
Further company coverage:  PUR1.WA 
 (Reporting by Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))